title: [Clinical outcomes of allogeneic hematopoietic stem cell transplantation for adult primary myelofibrosis: retrospective analysis by Fukuoka BMT group].
abstract: We retrospectively analyzed outcomes of eight evaluable patients with primary myelofibrosis (PMF) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), using different graft sources; four patients received peripheral blood stem cells, three bone marrow, and one umbilical cord blood. The median age was 48 years (range, 43~64 years). Seven patients had an intermediate or high Dupriez score. Three patients underwent myeloablative conditioning, whereas five underwent reduced-intensity conditioning regimens. Engraftment was obtained in all of these recipients. The median days to reach a neutrophil count above 0.5×10(9)/l and platelet count above 20×10(9)/l were 20 and 35 days, respectively. No treatment-related deaths were observed within 100 days after allo-HSCT. Two patients died of sepsis or late-onset non-infectious pulmonary complications. Four patients developed grade I to II acute GVHD, and six patients developed chronic GVHD. The estimated 3-year overall survival was 75% with a median follow up time of 43 months (range, 6~127). Four of 5 patients who were transfusion-dependent became free from transfusion after allo-HSCT. In six of seven patients, a regression of fibrosis was confirmed by bone marrow biopsy. Despite the small number of cases, our results suggested that allo-HSCT is an encouraging curative strategy for treating PMF.
authors.affiliation: Department of Hematology, Harasanshin Hospital, Fukuoka.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kamimura
authors.forename: Chong
authors.initials: C
authors.lastname: Yong
authors.forename: Yoshikiyo
authors.initials: Y
authors.lastname: Ito
authors.forename: Hideho
authors.initials: H
authors.lastname: Henzan
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Yusyu
authors.initials: Y
authors.lastname: Ohno
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Eto
authors.forename: Katsuto
authors.initials: K
authors.lastname: Takenaka
authors.forename: Koichi
authors.initials: K
authors.lastname: Akashi
mesh_terms: D000328:Adult; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome